$XLY.TO

Emblem Assuming DIP Lending Role From Auxly In Connection with CCAA Proceedings of Ayurcann

Red White & Bloom Brands' Subsidiary, Emblem, Assumes Debtor-In-Possession Financing for Ayurcann Following Assignment From Auxly Cannabis Group

Auxly Cannabis Q1 Net Income Falls, Despite Higher Revs

Auxly Cannabis Group (XLY.TO) had lower net income in the first quarter compared to a year earlier, when a deferred tax recovery was included, but revenue was up, the company said Thursday.For the three months ended March 31, 2026, the company reported net income of near $3.5 million or breakeven per basic and diluted share, compared with $12.1 million or EPS of $0.01, a year earlier.The company noted Q1 2025 included $8.1 million of deferred tax recovery related to the change in estimated useful life of intangible assets. Excluding the deferred tax recovery, net income decreased by $0.5 million primarily driven by higher fair value loss on biological transformation and inventory. Excluding the impact of fair value adjustments on biological transformation and inventory and the deferred tax recovery in 2025, net income increased $5.8 million primarily due to improved gross profits and the reduction in interest and accretion expenses, partially offset by higher SG&A.Total net revenue increased to near $39.8 million in Q1, compared with $32.7 million, a year-ago. The growth was primarily driven by higher incremental volumes across the core portfolio, improved pricing across the flower portfolio, partially offset by price compression on vape products, it said.Also, it had Adjusted EBITDA of $12.3 million, an increase of 65% and representing 31% of net revenue, and cash flow from operations before working capital changes of $11.3 million, an increase of 102%, representing 92% conversion from Adjusted EBITDA. It also cited gross margin on cannabis inventory sold of 55% and an Adjusted EBITDA margin of 31%."Our top line success can be attributed to the value proposition offered by Back Forty, contributions from new innovations like South Point and All-in-One Boosted Vapes and improved distribution," said Auxly Chief Executive Hugo Alves.Auxly expects to allocate between $10 million to $12 million of cash flow from operations towards capital projects at Auxly Leamington in 2026.Shares of the company were last seen unchanged at $0.14 on the Toronto Stock Exchange.

Earnings Flash (XLY.TO) Auxly Reports Q1 Revenue $39.8M, Up 22% YoY; Net Income of $3.5M or $0.003 per basic and diluted share

Auxly Cannabis Says TSX Approves Intention to Make Normal Course Issuer Bid

Auxly Cannabis Group (XLY.TO) on Tuesday said that the Toronto Stock Exchange accepted the company's notice of intention to make a normal course bid (NCIB).The company said it is permitted to buy back for cancellation, on the open market, during the period starting April 20, 2026, and ending on the earlier of April 19, 2027, and the completion of purchases under the NCIB, up to 68.9 million common shares of the company, representing less than 5% of its issued and outstanding common shares as of April 7, subject to the policies of the TSX.Auxly, as of April 7, had 1.41 billion issued and outstanding common shares and a "public float" of 1.05 billion common shares. It has also entered into an automatic share purchase plan with a designated broker to allow for the purchase of common shares under the NCIB at times when the company would ordinarily not be permitted to purchase shares due to regulatory restrictions or self-imposed blackout periods.Shares of the company edged down $0.005 or 4% to $0.12 on Monday on the TSX.

Auxly Cannabis Updated On Stalking Horse Bid for Assets of Ayurcann

Auxly Cannabis Group (XLY.TO) on Monday said that its stalking horse bid for the assets of Ayurcann Holdings Corp. (AYUR.CN) was not selected as the successful bid in the court-supervised sale process.As previously disclosed, the stalking horse bid was submitted in the Ayurcann sale process concurrently with Auxly providing debtor in possession financing to Ayurcann in a principal amount of up to $2.0 million.Pursuant to the terms of the sales process, Auxly's bid has been selected as the "Back-Up Bid" in accordance with the sale process rules and, should the successful bid not close by May 15, 2026, will be the winning bidder at its original stalking horse bid amount.As part of the closing of the successful bid, the DIP Facility will be repaid, including interest, by the successful bidder. Additionally, the Break Fee and Expense Reimbursement contemplated in the stalking horse bid will be paid to the company as part of the closing of the successful bid.Hugo Alves, CEO of Auxly, in a statement said: "Our stalking horse bid for Ayurcann was opportunistic in nature and contingent on exceeding our internal return thresholds. Our team will continue to pursue non-organic growth opportunities with vigilance where there is a strong strategic fit and, in the meantime, we can continue to focus on growing our business organically. We expect to generate significant free cash flow in 2026 and we are evaluating all our capital allocation alternatives to maximize shareholder value."Shares of Auxly were last seen unchanged at $0.125 on the Toronto Stock Exchange.